Faruqi & Faruqi Investigates Replimune Securities Class Action Lawsuit

Strategic Insights -

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL) following a federal securities class action filed against the Company. The lawsuit alleges that Replimune and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that the Company recklessly overstated the prospects of the IGNYTE trial. As a result, investors suffered damages when the true details entered the market.

Key Takeaways:

  • The lawsuit alleges that Replimune and its executives made false and/or misleading statements about the IGNYTE trial's prospects, which resulted in the FDA deeming the trial inadequate and not well-controlled.
  • The Company received a Complete Response Letter (CRL) from the FDA regarding the Biologics License Application (BLA) for RP1, stating that the IGNYTE trial is not considered an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.
  • As a result, Replimune's common stock plummeted over 73% during intraday trading on July 22, 2025.
  • The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class, who directs and oversees the litigation on behalf of the putative class.
  • Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice or choose to do nothing and remain an absent class member.
  • The deadline to seek the role of lead plaintiff is September 22, 2025.
  • Faruqi & Faruqi, LLP is encouraging anyone with information regarding Replimune's conduct to contact the firm, including whistleblowers, former employees, shareholders, and others.

Statistics:

  • Replimune's common stock plummeted over 73% during intraday trading on July 22, 2025.
  • The deadline to seek the role of lead plaintiff is September 22, 2025.
  • Faruqi & Faruqi, LLP has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • The firm has offices in New York, Pennsylvania, California, and Georgia.

Sources:

  • New York, New York--(Newsfile Corp. - August 18, 2025)
  • https://www.newsfilecorp.com/release/262933
  • www.faruqilaw.com
  • NASDAQ: REPL
  • U.S. Food and Drug Administration (FDA)
  • Replimune Group, Inc. (NASDAQ: REPL)